31 January 2000
Doubts over DuPont spin-off
DUPONT is on the point of abandoning plans to create a separate tracking stock for its life-sciences activities.
The rationale for the move was the potential for a much higher level of profit in such a grouping, which would cover pharmaceuticals and agrochemicals.
But since the time of the original announcement last year, market interest in life sciences companies has faded.
Charlies Holliday, chairman and chief executive, interviewed in the Financial Times, said the group is redefining itself as a science-based company in which biology will play an increasing role.